Sign In
Buy CYTK
$80.01
+0.84 (+1.06%)
At Close: Jun 23, 2026
Cytokinetics to Participate in September Investor Conferences
04:00pm, Wednesday, 27'th Aug 2025
SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following i
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025
07:30am, Monday, 25'th Aug 2025
Positive Results from MAPLE-HCM to be Shared in Hot Line Presentation Late Breaking Clinical Science Session to Present Incidence and Impact of Atrial Fibrillation Across Three Clinical Trials of Afic
Cytokinetics: Specialty Franchise With Aficamten And Ulacamten
08:00am, Wednesday, 20'th Aug 2025
CYTK's Aficamten is easily their main value driver. It has an oHCM PDUFA for December 26, 2025. Aficamten's late-cycle FDA meeting is in September. Plus, it has a potential future as a monotherapy, pe
Cytokinetics Names Jim Daly to Board of Directors
07:30am, Wednesday, 20'th Aug 2025
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the appointment of James M. Daly to its Board of Directors effective August 19,
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Tuesday, 19'th Aug 2025
SOUTH SAN FRANCISCO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 15, 2025 it granted stock options to purchase an aggregate of 10
Cytokinetics, Incorporated (CYTK) Q2 2025 Earnings Call Transcript
04:28pm, Friday, 08'th Aug 2025
Cytokinetics, Incorporated (NASDAQ:CYTK ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants & - Corporate Participant Andrew M. Callos - Executive VP & Chief Commercial O
Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates
06:10pm, Thursday, 07'th Aug 2025
Cytokinetics (CYTK) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $1.34. This compares to a loss of $1.31 per share a year ago.
Cytokinetics Reports Second Quarter 2025 Financial Results and Provides Business Update
04:00pm, Thursday, 07'th Aug 2025
Regulatory Reviews of Aficamten for Obstructive HCM Progressing in U.S., E.U. and China; Late-Cycle Meeting with U.S. FDA Scheduled for September Ahead of December 26, 2025 PDUFA Date
Cytokinetics Merits A Speculative Buy Rating
01:23pm, Friday, 25'th Jul 2025
Cytokinetics continues to near unaminous positive analyst sentiment, with most price targets well above current levels, reflecting strong growth expectations. The company's NDA around its lead drug ca
Cytokinetics to Announce Second Quarter Results On August 7, 2025
04:00pm, Thursday, 24'th Jul 2025
SOUTH SAN FRANCISCO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 7, 2025 at 4:00
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:00pm, Friday, 18'th Jul 2025
SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 16, 2025 it granted stock options to purchase an aggregate of 131,
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025
07:30am, Thursday, 10'th Jul 2025
Hot Line Presentation of MAPLE-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Tuesday, 17'th Jun 2025
SOUTH SAN FRANCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 15, 2025 it granted stock options to purchase an aggregate of 83,5
Cytokinetics, Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - CYTK
07:55am, Tuesday, 17'th Jun 2025
NEW YORK, NY / ACCESS Newswire / June 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) c
CYTK ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Cytokinetics, Incorporated Shareholders Who Lost Money
07:55am, Monday, 16'th Jun 2025
NEW YORK, NY / ACCESS Newswire / June 16, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) c
